Webinar 2021
Webinar: preventing and managing long-term organ damage in lupus
Watch footage from our recent webinar for unmissable expert insights into the importance of minimising the accrual of irreversible organ damage in patients with lupus.
- Understand unmet needs in lupus management with Professor Michelle Petri
- Learn more about organ damage management strategies with Professor Richard Furie
- Find out about treatment sequencing considerations in lupus from Professor Daniel Wallace
Welcome and Introduction
Webinar chair, Professor Michelle Petri welcomes the audience and introduces her colleagues, Professors Richard Furie and Daniel Wallace.
Discover more about the unmet needs that remain in systemic lupus erythematosus (SLE).
SLE: where are we now?
Professor Michelle Petri explains that, while impressive progress has been made in the field of lupus in recent decades, there is still a lot more work to be done.
Management of non-renal lupus
Professor Petri explains how non-renal lupus is currently managed and discusses current problems in SLE management. Discover how new approaches for non-renal lupus could help to address these problems.
Management of renal lupus and rare disease manifestations
Loss of nephrons is irreversible making renal remission an important therapeutic target for patients with kidney involvement. There are also challenges associated with treatment of rarer types of lupus, such as central-nervous system manifestations.
Treat-to-target in systemic lupus erythematosus
Professor Petri describes how the introduction of a treat-to-target strategy has benefitted patients with rheumatoid arthritis and explains her ambition to implement a similar treat-to-target strategy in the management of lupus.
Type II symptoms of lupus
Professor Petri provides a brief overview of the type II symptoms of lupus and explains how addressing these can help improve patient quality of life.
Preventing and managing long-term organ damage in SLE
Professor Richard Furie offers an insightful look at the strategies that are currently available for the prevention and management of long-term organ damage in systemic lupus erythematosus (SLE).
Long-term organ damage in lupus
Professor Furie explains that damage in lupus cannot be reversed, highlighting the importance of preventing organ damage accrual in patients wherever possible.
Predicting damage accrual in lupus
Is it possible to determine which patients are at greatest risk of developing long-term organ damage? Professor Furie discusses the progress that has been made in identifying predictors of enhanced damage accrual in lupus.
Lupus comorbidities
Comorbidities, such as cardiovascular disease and stroke, can further complicate the management of lupus. Improve your knowledge of how comorbidities impact patients with lupus from Professor Furie.
Mortality in lupus
Professor Furie explains that although mortality rates have improved significantly in recent years, the number of early deaths that occur as a result of lupus remains unacceptably high.
Preventing long-term organ damage in lupus
Professor Furie discusses the latest strategies to prevent the development of irreversible organ damage in patients with lupus, including the role of belimumab in lupus management.
Considerations for treatment sequencing in lupus
Join Professor Daniel Wallace as he takes a closer look at how treatment should be sequenced in patients with systemic lupus erythematosus (SLE) and examines guideline recommendations for the management of this disease.
Non-pharmacological interventions for lupus
Professor Wallace explores the non-pharmacological interventions that can be used to help improve patient outcomes in lupus, including education, diet and exercise.
Principles of lupus management
The management of lupus involves a combination of physical measures, medication, counselling and, where necessary, surgery. In the following video, Professor Wallace provides a clear overview of the general principles that underpin lupus management.
Treatment goals in lupus
Take a deeper dive into lupus management and understand the current aims of treatment for this disease with Professor Wallace.
Lupus nephritis management
What about lupus nephritis? Professor Wallace explores management strategies and treatment goals for patients with kidney involvement. These include prevention and treatment of flares and comorbidities, controlling refractory disease, and avoiding secondary morbidity and mortality.
Current unmet needs in lupus
What more needs to be done to improve lupus management? In the following video, Professor Wallace highlights the unmet needs that still exist in the management of lupus.
Q&A Session
Following our three expert presentations, the live audience was given the opportunity to submit questions to the panel for discussion. Watch the video to find out what they had to say.
The contents of this video are outlined below for ease of navigation:
- Where do we stand with therapeutic blood monitoring in lupus? (00:00–02:10)
- What approach is best when tapering prednisone? (02:10–03:31)
- Are there any specific predictive tools for renal outcome in lupus nephritis? (03:31–06:59)
- How do you manage lupus and COVID-19? (06:59–10:48)
- Are there any lupus medications in the pipeline that you consider particularly promising? (10:48–15:35)
- Which type II symptom has the most profound patient effect? (15:35–16:35)
- Closing statement (16:35–17:19)
This content has been developed independently by Medthority who previously received educational funding from GlaxoSmithKline Biologicals SA (GSK) in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.